Detalhe da pesquisa
1.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet
; 390(10101): 1499-1510, 2017 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28750935
2.
Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.
Eur J Immunol
; 44(9): 2802-10, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25042008
3.
Tropism Switching Is Rare in Aviremic HIV-Infected Patients Virologically Suppressed With Non-Entry-Inhibiting Antiretroviral Regimens.
Ann Pharmacother
; 54(12): 1263-1264, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32462896
4.
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
BMC Infect Dis
; 13: 269, 2013 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23741991
5.
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Antivir Ther
; 13(2): 297-306, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18505181
6.
Clinical and morphologic findings in disseminated Scedosporium apiospermum infections in immunocompromised patients.
Proc (Bayl Univ Med Cent)
; 27(3): 253-6, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24982580
7.
Herpes simplex virus meningitis complicated by ascending paralysis.
Proc (Bayl Univ Med Cent)
; 26(3): 265-7, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23814385
8.
Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells.
AIDS
; 27(13): 2041-51, 2013 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23615121
9.
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
AIDS Res Hum Retroviruses
; 29(2): 350-8, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23039030
10.
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
AIDS
; 25(14): 1737-45, 2011 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21716073
11.
Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.
J Immunol Methods
; 365(1-2): 27-37, 2011 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-21093448
12.
Central nervous system tuberculosis.
Proc (Bayl Univ Med Cent)
; 23(4): 359-60, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20944756
13.
Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730.
AIDS Res Hum Retroviruses
; 26(8): 841-5, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20672994
14.
Primary effusion lymphoma diagnosed by pericardiocentesis.
Proc (Bayl Univ Med Cent)
; 22(1): 77-80, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19169406
15.
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
AIDS Res Hum Retroviruses
; 25(4): 395-403, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19320570
16.
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
AIDS
; 23(12): 1547-56, 2009 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-19542866
17.
Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
J Acquir Immune Defic Syndr
; 51(2): 163-74, 2009 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19357529
18.
Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.
J Acquir Immune Defic Syndr
; 41(1): 127-9, 2006 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16340487